Peritoneal Mesothelioma After CRS/HIPEC: 5-Year Survival Reaches 77% in 2026 Data

Peritoneal mesothelioma is a rare and aggressive cancer of the abdominal lining. It accounts for approximately 20–30% of all mesothelioma cases and was historically considered nearly incurable with conventional treatment. The introduction of cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy — known as CRS/HIPEC — changed that picture fundamentally. At high-volume specialized centers, 5-year survival rates now reach 40–77% in carefully selected patients. This article explains what the procedure involves, who qualifies, and what the 2026 survival data shows. For a foundational overview of the procedure, see WikiMesothelioma's Heated Chemotherapy (HITHOC and HIPEC) guide.

What Are the Key Facts About Peritoneal Mesothelioma in 2026?

What Is Peritoneal Mesothelioma and How Is It Different From Pleural Disease?

Peritoneal mesothelioma develops in the peritoneum — the thin membrane lining the abdominal cavity and coating the abdominal organs. It is distinct from the more common pleural mesothelioma, which affects the lung lining. Peritoneal disease presents differently: the primary symptoms are abdominal pain, bloating, unexplained weight loss, ascites (fluid accumulation in the abdomen), and bowel or digestive changes rather than the chest pain and shortness of breath typical of pleural disease.

Pathologically, peritoneal mesothelioma is classified into the same histological subtypes as pleural disease — epithelioid (approximately 80% of cases), sarcomatoid (rare, <5%), and biphasic/mixed. Histological subtype is one of the strongest prognostic factors. Understanding the different mesothelioma types is foundational to treatment planning: see WikiMesothelioma's Mesothelioma Types guide.

The treatment approach for peritoneal disease is fundamentally different from pleural mesothelioma. While pleural disease is primarily treated with surgery (pleurectomy/decortication or extrapleural pneumonectomy) and systemic therapy, peritoneal disease is best addressed with CRS/HIPEC — a procedure that targets the peritoneum as a contained anatomical compartment. The peritoneal cavity's semi-closed nature makes regional treatment with heated chemotherapy particularly effective.

What Does CRS/HIPEC Involve?

CRS/HIPEC is a two-part procedure performed in a single operative session lasting 6–12 hours.

Phase 1 — Cytoreductive Surgery (CRS): The surgical team systematically removes all visible tumor from the peritoneal surfaces, including any tumor coating the bowel, liver surface, diaphragm, pelvis, and abdominal wall. The extent of the operation depends on tumor distribution. When complete tumor removal (CC-0) is achieved, the foundation for the best possible outcomes is established. If only partial cytoreduction is achievable (CC-1 or CC-2), outcomes diminish substantially.

Phase 2 — HIPEC: Immediately following the surgical phase, heated chemotherapy solution is circulated through the abdominal cavity at a temperature of 41–43°C for 60–90 minutes. The most commonly used agents for peritoneal mesothelioma are cisplatin (often at 100 mg/m²) and/or doxorubicin. The heat serves multiple purposes: it enhances drug penetration into microscopic tumor deposits, increases cytotoxicity of the chemotherapy agents, and damages residual cancer cell membranes. Unlike systemic chemotherapy, HIPEC delivers drug concentrations 20–1,000 times higher locally than what would be tolerated intravenously.

The full surgical and technical details are covered in WikiMesothelioma's Mesothelioma Surgery Overview.

"What I tell families considering CRS/HIPEC is that it's not a minor procedure — it's a major commitment. But the data is unmistakable. For the right patient at the right center, this is genuinely curative-intent surgery. We're seeing people who were told they had less than a year who are now five or ten years out. The completeness of cytoreduction is what determines whether we're in the 100-month column or the 2.7-month column."

What Determines Who Is Eligible for CRS/HIPEC?

Patient selection is the most critical factor determining whether CRS/HIPEC will be beneficial. Eligibility criteria are based on the Peritoneal Cancer Index, histological subtype, disease extent, and the patient's overall health.

The Peritoneal Cancer Index (PCI) is a 0–39 scoring system developed by Dr. Paul Sugarbaker that assesses tumor burden across 13 abdominal and pelvic regions. Each region receives a lesion size score from 0 (no tumor) to 3 (confluence >5 cm). A PCI score of 20 or below is associated with a median overall survival of 103 months after CRS/HIPEC. A PCI of 21–39 is associated with 33 months. Patients with PCI >20–25 are generally not considered for curative cytoreductive surgery.

Histological subtype is equally important. Epithelioid disease carries median survivals of 16–58+ months after CRS/HIPEC. Sarcomatoid disease (rare in peritoneal mesothelioma) carries median survival of only 2–5 months even with aggressive treatment and is generally not considered for CRS/HIPEC. Biphasic disease is intermediate.

Additional contraindications to CRS/HIPEC include extra-abdominal disease spread, extensive small bowel mesenteric involvement (which may preclude complete cytoreduction while preserving adequate bowel function), and cardiac or pulmonary conditions that preclude tolerating a 6–12 hour major surgery. A staging laparoscopy is often performed before committing to open CRS/HIPEC to confirm disease distribution and PCI.

"PCI is the number families need to understand. A PCI of 10 means something very different from a PCI of 30. Both are peritoneal mesothelioma, but the treatment approach and the expected outcome are completely different. Getting an evaluation at a center that does this regularly — not one that does two or three cases a year — is the difference between knowing your actual options and not knowing them."

How Do Survival Outcomes Compare Across Treatment Approaches?

The survival difference between CRS/HIPEC and systemic chemotherapy alone is striking and well-established by 2026.

Without CRS/HIPEC:

• Historical median survival (no treatment): under 12 months
• Systemic chemotherapy (pemetrexed/cisplatin or carboplatin): median OS 13–16 months, overall response rate approximately 38%
• Pembrolizumab in pretreated peritoneal mesothelioma: ORR 21%, median OS 20.9 months (JAMA Network Open, 2023)

With CRS/HIPEC:

• Overall median OS across multiple high-volume center series: 38–103 months
• 5-year OS in optimally selected patients: 40–77%
• CC-0 cytoreduction achieved: median OS >100 months at major centers
• CC-1 (minimal residual disease <2.5 mm): median OS approximately 30 months
• CC-2 (gross residual disease): median OS approximately 2.7 months — essentially no benefit from the surgical procedure

With CRS/HIPEC plus NIPEC:

Normothermic intraperitoneal chemotherapy (NIPEC), delivered long-term via an implanted intraperitoneal port using pemetrexed and cisplatin, is an adjunctive strategy pioneered at the Washington Cancer Institute by Dr. Paul Sugarbaker. When added to CRS/HIPEC for selected patients, NIPEC has been reported to extend 5-year survival rates toward 80%. NIPEC is not universally available and is primarily offered at specialized peritoneal surface malignancy programs.

For patients with unresectable or recurrent peritoneal mesothelioma, Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) is emerging as a minimally invasive palliative approach. PIPAC delivers chemotherapy in aerosolized form through laparoscopic ports, achieving high peritoneal drug concentrations with minimal systemic toxicity. Documentation from the NCI StatPearls HIPEC reference covers the technical basis for regional peritoneal chemotherapy delivery.

What Role Does Immunotherapy Play in Peritoneal Mesothelioma?

Immunotherapy has become an important option for peritoneal mesothelioma patients who are not surgical candidates or who have progressed after CRS/HIPEC.

The FDA approved nivolumab plus ipilimumab (CheckMate 743) as first-line therapy for unresectable pleural mesothelioma in October 2020. Evidence increasingly supports its use in peritoneal disease, though the original approval was for pleural. The combination produced a median overall survival of 18.1 months vs. 14.1 months for chemotherapy in the CheckMate 743 trial, with particularly strong benefit in non-epithelioid histology (biphasic and sarcomatoid).

For pretreated peritoneal mesothelioma specifically, pembrolizumab monotherapy demonstrated an objective response rate of 21% and median overall survival of 20.9 months from treatment initiation in a 2023 JAMA Network Open study — a meaningful improvement over historical second-line outcomes. Active clinical trials as of 2025–2026 are investigating immunotherapy combinations (atezolizumab, durvalumab/tremelimumab) specifically for peritoneal disease. For an up-to-date overview of active trials, see the NCI mesothelioma clinical trials database.

"The immunotherapy data for peritoneal mesothelioma is developing faster than most people realize. Pembrolizumab's 20.9-month median OS in pretreated patients would have been considered remarkable just a few years ago. Combined with what we're seeing from PIPAC, patients who are not CRS/HIPEC candidates now have real options beyond standard chemotherapy."

Which Treatment Centers Specialize in CRS/HIPEC for Peritoneal Mesothelioma?

Surgical volume is directly correlated with outcomes in CRS/HIPEC. Centers performing the highest number of peritoneal mesothelioma CRS/HIPEC procedures annually demonstrate the best survival outcomes. The key reason is that complete cytoreduction (CC-0) requires extensive surgical expertise — it is not a procedure where individual surgeon experience transfers easily from general surgical oncology.

Leading specialized centers include:

• Washington Cancer Institute (MedStar Washington Hospital Center), Washington, D.C. — The founding center for CRS/HIPEC, established by Dr. Paul Sugarbaker, who pioneered both the PCI scoring system and the NIPEC protocol.
• MD Anderson Cancer Center, Houston, TX — High-volume center with dedicated peritoneal surface malignancy program.
• Memorial Sloan Kettering Cancer Center, New York, NY — Extensive mesothelioma program including peritoneal disease.
• Brigham and Women's Hospital, Boston, MA — One of the top mesothelioma surgical programs nationally.
• Mayo Clinic, Rochester, MN — Comprehensive peritoneal malignancy program.
• University of Pittsburgh Medical Center (UPMC), Pittsburgh, PA — Major peritoneal surface malignancy program.

Patients should seek centers performing at least 20–30 peritoneal mesothelioma CRS/HIPEC procedures annually. A second opinion from a specialized center should be obtained before any treatment decision, particularly when an initial assessment suggests the PCI may be above 20. The staging laparoscopy, if not already performed, can definitively determine CRS/HIPEC eligibility. For guidance on diagnosis and staging before treatment planning, review WikiMesothelioma's Understanding Your Diagnosis resource and the Mesothelioma Diagnosis and Staging guide.

What Are the Next Steps After a Peritoneal Mesothelioma Diagnosis?

Time matters for peritoneal mesothelioma patients. The workup, staging evaluation, and referral to a specialized center should happen within weeks of diagnosis, not months. Key steps:

1. Confirm the diagnosis with pathology: Immunohistochemistry markers (calretinin, WT-1, D2-40) are essential to confirm peritoneal mesothelioma vs. other peritoneal cancers. If the pathology was done at a community hospital, have slides reviewed at a specialized center.
2. Request a PCI assessment: CT of the chest, abdomen, and pelvis with contrast provides the preoperative PCI estimate. This single number determines the surgical pathway.
3. Seek evaluation at a specialized center: Contact a center with a dedicated peritoneal surface malignancy program. Many offer telemedicine consultations and can review imaging remotely before an in-person visit.
4. Consult a mesothelioma legal team simultaneously: Asbestos exposure is the primary cause of peritoneal mesothelioma. Asbestos trust fund claims and potential lawsuits should be evaluated immediately — compensation can help cover treatment costs, travel expenses, and family financial needs during treatment. Start with a free case assessment or visit our mesothelioma lawyers directory.
5. Inquire about clinical trials: For patients with PCI above 20 or non-epithelioid histology, clinical trials may be the best option for accessing newer immunotherapy or targeted therapy combinations.

References

1. Heated Chemotherapy (HITHOC and HIPEC) — WikiMesothelioma
2. Mesothelioma Types — WikiMesothelioma
3. Mesothelioma Surgery Overview — WikiMesothelioma
4. Mesothelioma Statistics Explorer — NCI SEER
5. Peritoneal Mesothelioma Treatment PDQ — National Cancer Institute
6. Cytoreductive Surgery and HIPEC — NCI StatPearls
7. CRS Outcomes for Peritoneal Mesothelioma — Journal of Clinical Oncology (PMID 19917864)
8. Opdivo (Nivolumab) FDA Drug Approval — U.S. Food and Drug Administration
9. Understanding Your Mesothelioma Diagnosis — WikiMesothelioma
10. Mesothelioma Diagnosis and Staging — WikiMesothelioma
11. Mesothelioma Clinical Trials — National Cancer Institute
12. Pleurectomy and Decortication — WikiMesothelioma